76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Zoetis Inc
Closed
SectorHealthcare
155.91 -0.92
Overview
Share price change
24h
Min
155.03
Max
157.51
Income | 50M 631M |
|---|---|
Sales | -97M 2.2B |
P/E Sector Avg | 28.248 50.291 |
EPS | 1.409 |
Dividend yield | 1.27 |
Profit margin | 28.423 |
Employees | 13,800 |
EBITDA | 72M 983M |
Recommendations | Strong Buy |
|---|---|
12 Months Forecast | +19.41% upside |
Dividend yield Sector Avg | 1.27% 2.40% |
|---|---|
Next Earnings | 5 Aug 2025 |
Next Dividend date | 3 Sept 2025 |
Next Ex Dividend date | 18 Jul 2025 |
Market Cap | -2.5B 70B |
|---|---|
Previous open | 156.83 |
Previous close | 155.91 |
Technical Score
By Trading Central
Confidence
Bullish Evidence
Zoetis Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Zoetis Inc Forecast
Price Target
By TipRanks
19.41% upside
12 Months Forecast
Average 187.75 USD 19.41%
High 210 USD
Low 160 USD
Based on 9 Wall Street analysts offering 12 month price targets forZoetis Inc - Dist in the last 3 months.
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Zoetis Inc
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
